8-K: ARS Pharma Q3 Revenue Soars on neffy Sales, Strong Cash

ARS Pharmaceuticals reported robust third-quarter 2025 financial results, driven by significant neffy U.S. net product revenue and strong commercial launch progress, supported by a substantial cash position.

Summary

• Total revenue for Q3 2025 reached $32.5 million, including $31.3 million in neffy U.S. net product revenue.
• The company reported a net loss of $51.2 million, or $0.52 per share, for the third quarter of 2025.
• Cash, cash equivalents, and short-term investments stood at $288.2 million as of September 30, 2025, anticipated to fund operations through cash-flow breakeven.
• Consumer awareness of neffy significantly increased from approximately 20% pre-campaign to 56% as of September 2025 due to direct-to-consumer (DTC) investments.
• Over 18,000 healthcare providers (HCPs) have prescribed neffy to date, an 86% increase from August 2025.
• neffy received approval in Japan in September 2025, with launch expected in Q4 2025, and EURneffy 2 mg successfully launched in the U.K. in October 2025.
• A Phase 2b clinical trial for intranasal epinephrine technology (ARS-2) in urticaria is ongoing, with topline data anticipated in mid-2026.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to strong revenue growth for neffy, significant increases in consumer awareness and HCP adoption, successful global expansion, and a robust cash position that is expected to fund operations to breakeven. While there is a net loss, it is attributed to strategic, aggressive investment in commercialization, which is a positive indicator for future growth.

Positives

• Strong total revenue of $32.5 million in Q3 2025, with $31.3 million from neffy U.S. net product sales, demonstrating significant commercial traction.
• Substantial cash, cash equivalents, and short-term investments of $288.2 million as of September 30, 2025, providing a runway through expected cash-flow breakeven.
• Significant increase in consumer awareness of neffy, growing from 20% to 56% since the DTC campaign launch.
• Rapid expansion of prescriber base, with over 18,000 HCPs prescribing neffy, an 86% increase from August 2025.
• Successful global expansion with neffy approval in Japan and EURneffy launch in the U.K., two major markets.
• Real-world evidence data presented at ACAAI showed approximately 90% of patients with anaphylaxis were effectively treated with a single dose of neffy, comparable to epinephrine injection.
• Introduction of the 'Get neffy on Us' campaign, offering a free virtual prescriber option and $0 co-pay to reduce patient barriers.
• Expansion into schools with the neffyinSchools program, providing free doses for emergency use in over 6,500 schools.

Negatives

• Reported a net loss of $51.2 million for the third quarter of 2025, primarily due to substantial investment in national DTC marketing and sales expenses.
• Selling, General and Administrative (SG&A) expenses were high at $74.8 million, reflecting aggressive commercialization efforts.

Risks

• Potential safety and other complications from neffy.
• Ability to maintain regulatory approval for neffy in its currently approved indications.
• The scope, progress, and expansion of developing and commercializing neffy.
• Risk that the expected return on investment from the DTC campaign may not be realized.
• The scope, progress, and expansion of developing intranasal epinephrine technology.
• Clinical trial results may not be favorable or indicative of future outcomes.
• Potential for governments and payors to delay, limit, or deny coverage or reimbursements for neffy.
• The size and growth of the market for neffy and the rate and degree of market acceptance thereof vis-à-vis intramuscular injectable products.
• Ability to protect intellectual property position.
• Impact of government laws, regulations, and policies.

Future Outlook

ARS Pharmaceuticals anticipates continued acceleration of neffy's U.S. growth in 2026, driven by ongoing DTC campaigns, dissemination of real-world evidence, and seamless prescribing experiences. The company expects to achieve unrestricted payor access while maintaining a gross-to-net retention of at least 50%. Regulatory approvals for neffy are expected in Canada and China in the first half of 2026, with launches following. The EMA's decision for EURneffy 1 mg is anticipated in the first half of 2026. Topline data from the Phase 2b urticaria trial is expected in mid-2026, potentially expanding the intranasal epinephrine technology into a new indication with multi-billion dollar sales potential.

Management Comments

• "We are executing our commercial strategy across multiple fronts, with each element reinforcing the others to drive momentum."
• "Our direct-to-consumer campaigns are generating measurable increases in patient awareness; real-world evidence data are further strengthening prescriber confidence in neffy's effectiveness; and we are implementing advertising programs such as a free virtual prescriber option and zero dollar co-pay to further reduce barriers for patients."
• "When healthcare providers want their patients to have neffy, we are able to assist and address potential obstacles."

Industry Context

The announcement highlights neffy's role in addressing significant unmet needs in the Type I allergic reaction patient population, particularly for those who delay or do not administer epinephrine due to limitations of traditional auto-injectors (e.g., fear of needles, portability issues, user error). neffy's needle-free, easy-to-use design aims to expand the epinephrine market beyond current auto-injector users, targeting both active prescribers and a large segment of diagnosed but untreated patients. The company's strategy aligns with broader trends towards patient-centric, less invasive treatment options and increased awareness campaigns for life-threatening conditions.

Comparison to Industry Standards

• Real-world data from 680 patients showed that approximately 90% of patients experiencing anaphylaxis were effectively treated with a single dose of neffy, which is reported as indistinguishable from historically reported epinephrine injection outcomes.
• neffy offers a 'no needle, no injection' solution, addressing limitations of epinephrine auto-injectors (EAIs) such as fear of needles, risk of needle-related injuries, and user error (23%-35% failure rate for EAIs).
• Patient surveys indicate 87% of neffy users are likely to refill, compared to actual EAI refill rates which are often lower, suggesting higher patient satisfaction and adherence.
• neffy is expanding the epinephrine market, with 26% of its patients coming from 'lapsed/non-filler' or 'never Rx' segments, indicating it reaches patients not adequately served by existing EAI products.
• The company estimates a potential multi-billion dollar U.S. market opportunity ($3.5B+ in initial addressable segments and $7B+ in expansion segments) for neffy, significantly larger than the current EAI market.

Related Party Transactions

• Accounts payable and accrued liabilities include related party amounts of $4,269 thousand as of September 30, 2025 (compared to $656 thousand as of December 31, 2024).
• Term loans, net, include related party amounts of $4,811 thousand as of September 30, 2025 (compared to $0 as of December 31, 2024).
• Cost of goods sold includes related party amounts of $2,046 thousand for Q3 2025 and $3,400 thousand for the nine months ended September 30, 2025.
• Research and development expenses include related party amounts of $559 thousand for Q3 2025 and $1,804 thousand for the nine months ended September 30, 2025.
• Selling, general and administrative expenses include related party amounts of $123 thousand for Q3 2025 and $354 thousand for the nine months ended September 30, 2025.
• Other income (expense), net, includes related party amounts of $(3) thousand for Q3 2025 and for the nine months ended September 30, 2025.

Stakeholder Impact

• **Shareholders:** Strong revenue growth and a healthy cash balance provide confidence in the company's commercial strategy and long-term potential, despite current net losses due to investment. The loan facility from major shareholders indicates continued support.
• **Patients:** Increased access to neffy through DTC campaigns, virtual prescriber options, $0 co-pay programs, and school initiatives improves the availability of a needle-free alternative for anaphylaxis, potentially leading to better treatment adherence and outcomes.
• **Healthcare Providers (HCPs):** Growing awareness and real-world evidence support for neffy's effectiveness are likely to increase prescriber confidence and adoption, simplifying the treatment paradigm for Type I allergic reactions.
• **Employees:** Continued investment in commercialization and R&D suggests stability and potential growth opportunities within the company.
• **Partners (ALK, Alfresa, Pediatrix):** Successful global launches and anticipated approvals strengthen partnerships and validate the global market potential of neffy.

Next Steps

• Continue investment in neffy promotion to further expand patient and physician awareness and accelerate market share growth.
• Achieve unrestricted payor access while maintaining steady-state gross-to-net retention guidance of at least 50%.
• Alfresa expects neffy to be available in Japan in the fourth quarter of 2025.
• Anticipate regulatory approval for EURneffy 1 mg for children by the EMA in the first half of 2026.
• Expect regulatory approvals for neffy in Canada (with ALK-Abell) in Q1 2026, with launch in H1 2026.
• Expect regulatory approval for neffy in China (with Pediatrix) in H1 2026.
• Continue enrolling patients in the Phase 2b trial for intranasal epinephrine technology as a treatment for acute flares in chronic spontaneous urticaria, with topline data anticipated in mid-2026.

Key Dates

Recommendation

The company demonstrates strong commercial momentum with neffy, evidenced by significant revenue growth, rapidly increasing consumer awareness, and a substantial expansion in the number of prescribing healthcare providers. The strategic investment in DTC marketing, while leading to a net loss, is a calculated move to capture a large, underserved market, and the robust cash position of $288.2 million provides a clear runway to cash-flow breakeven. Global expansion with approvals and launches in key markets further de-risks the growth trajectory. The real-world data supporting neffy's effectiveness, coupled with initiatives to reduce patient barriers, positions the company for continued market share gains and long-term value creation. The potential for expansion into the urticaria indication represents additional significant upside.

Keywords

neffy, epinephrine nasal spray, anaphylaxis, biopharmaceutical, Q3 earnings, allergic reactions, FDA approved, commercial launch, DTC marketing, pharmaceuticals